Rating Rationale
July 08, 2020 | Mumbai
Sundyota Numandis Probioceuticals Private Limited
Rating upgraded to 'CRISIL BBB-/Stable'
 
Rating Action
Total Bank Loan Facilities Rated Rs.52.5 Crore
Long Term Rating CRISIL BBB-/Stable (Upgraded from 'CRISIL BB+/Stable')
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has upgraded its rating on the long-term bank facilities of Sundyota Numandis Probioceuticals Private Limited (SDN Probio) to 'CRISIL BBB-/Stable' from 'CRISIL BB+/Stable'.
 
The upgrade reflects completion of capex in respect of manufacturing unit which has become operation from February 2020, and will be supporting operating performance from FY21 onwards. The company has an established market position in the nutraceuticals market and with growing emphasis on nutraceuticals in the current scenario, it will be supporting operating performance over the medium term.
 
The rating continues to reflect extensive industry experience of the promoters, healthy profitability supported by established market position and average financial risk profile. These strengths are partially offset by moderate scale of operations and large working capital requirements.

Key Rating Drivers & Detailed Description
Strengths: 
* Established industry experience of the promoters: The promoters have been in the business for more than decade and have established track record. SDN Probio has introduced successfully several niche nutraceuticals and probiotic products in Indian market after forging alliances with leading global nutraceutical/probiotic companies on an exclusive basis. CRISIL believes that company will continue to benefit from the promoter's experience and established relationships with customers.
 
* Healthy profitability supported by established market position: The company has healthy profitability and operating efficiencies, marked by healthy return on capital employed (RoCE) at around 21% in fiscal 2020 and operating margins in the range of 12-16 per cent for the past 3 years ended as on March 2020. It is supported by established market position as the company has exclusive rights for production and marketing of many products in India.
 
* Average financial risk profile: The company has average financial profile marked by networth of around Rs 35 Cr in FY20. Gearing is moderate which stood at around 1.2 times as on 31st Mar, 2020. Debt-protection metrics remained healthy marked by interest coverage of 7.5 times as on 31st Mar, 2020.
 
Weaknesses:
* Moderate scale of operations: Though the company's scale of operations is improving since fiscal 2016 but continues to remain moderate at around Rs.77 Cr. in fiscal 2020. In the light of the COVID-19 outbreak, the company has been operational as it deals in nutraceuticals. The company's ability to ramp-up scale of operations will remain a key monitorable.
 
* Large working capital requirement: The company has large working capital requirements as indicated by GCAs of around 150 days in fiscal 2020, mostly driven by receivables of around 80 days.
Liquidity Adequate

Bank limit utilisation is low at around 74 percent for the past twelve months ended April 2020. Cash accrual are expected to be over Rs 7.7 Cr which is sufficient against term debt obligation of Rs 2.5 Cr over the medium term. In addition, it will support incremental working capital requirements of the company. Current ratio is moderate at 1.57 times on March 31, 2020. The company has availed of moratorium for three months ended May 31, 2020 for term-debt rapayments, but has not extended it. The company has also applied for Covid-19 contingency funds for around 20% of the current facilities.

Outlook: Stable

CRISIL believes SDN Probio will continue to benefit from the extensive experience of its promoter, and established market position in the nutraceuticals market.

Rating Sensitivity factors
Upward factor
* Sustained improvement in operating income along with sustenance of operating profitability leading to higher accruals over Rs 12 Cr
* Sustenance of healthy financial risk profile
   
Downward factors
* Large, debt-funded capital expenditure or stretched working capital cycle weakens the capital structure with TOLTNW deteriorating to the range of 2.5 times.
* Dip in operating profitability of the company.
About the Company

Founded in 2011, SDN Probio is engaged in the business of marketing a range of niche nutraceuticals and probiotics in India. The company is promoted by Mr. Dinesh Kumar and has over 25 years of experience in the pharmaceutical and nutraceutical sector.

Key Financial Indicators
As on / for the period ended March 31   2019 2018
Operating income Rs crore 64.71 51.95
Reported profit after tax Rs crore 6.06 5.44
PAT margins % 9.37 10.40
Adjusted Debt/Adjusted Net worth Times 0.45 0.45
Interest coverage Times 10.62 14.63

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments and are included (where applicable) in the Annexure -- Details of Instrument in this Rating Rationale. For more details on the CRISIL complexity levels, please visit www.crisil.com/complexity-levels.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of
Allotment
Coupon Rate (%) Maturity Date Issue Size
(Rs Cr)
Complexity
Levels
Rating Assigned with Outlook
NA Cash Credit NA NA NA 11.00 NA CRISIL BBB-/Stable
NA Term Loan NA NA Mar-2026 41.50 NA CRISIL BBB-/Stable
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  52.50  CRISIL BBB-/Stable      03-04-19  CRISIL BB+/Stable    --    --  -- 
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Cash Credit 11 CRISIL BBB-/Stable Cash Credit 11 CRISIL BB+/Stable
Term Loan 41.5 CRISIL BBB-/Stable Term Loan 41.5 CRISIL BB+/Stable
Total 52.5 -- Total 52.5 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
CRISILs Approach to Recognising Default
CRISILs Criteria for rating short term debt
Mapping global scale ratings onto CRISIL scale

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Rahul Guha
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Neha Sharma
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 79 4024 4509
neha.sharma@crisil.com


Vaibhav Gupta
Rating Analyst - CRISIL Ratings
CRISIL Limited
B:+91 20 4018 1900
Vaibhav.Gupta@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL